$19.56
1.95% yesterday
Nasdaq, Sep 27, 10:00 pm CET
ISIN
US14888U1016
Symbol
CPRX
Sector
Industry

Catalyst Pharmaceuticals, Inc. Stock price

$19.56
-0.91 4.45% 1M
+3.29 20.22% 6M
+2.75 16.36% YTD
+7.39 60.72% 1Y
+14.37 276.88% 3Y
+14.29 271.16% 5Y
+16.57 554.18% 10Y
Nasdaq, Closing price Fri, Sep 27 2024
-0.39 1.95%
ISIN
US14888U1016
Symbol
CPRX
Sector
Industry

Key metrics

Market capitalization $2.37b
Enterprise Value $2.00b
P/E (TTM) P/E ratio 37.39
EV/FCF (TTM) EV/FCF 12.44
EV/Sales (TTM) EV/Sales 4.59
P/S ratio (TTM) P/S ratio 5.45
P/B ratio (TTM) P/B ratio 3.88
Revenue growth (TTM) Revenue growth 43.42%
Revenue (TTM) Revenue $434.48m
EBIT (operating result TTM) EBIT $85.88m
Free Cash Flow (TTM) Free Cash Flow $160.47m
Cash position $375.69m
EPS (TTM) EPS $0.53
P/E forward 18.17
P/S forward 5.00
EV/Sales forward 4.22
Short interest 6.04%
Show more

Is Catalyst Pharmaceuticals, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,901 stocks worldwide.

Catalyst Pharmaceuticals, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Catalyst Pharmaceuticals, Inc. forecast:

7x Buy
100%

Analyst Opinions

7 Analysts have issued a Catalyst Pharmaceuticals, Inc. forecast:

Buy
100%

Financial data from Catalyst Pharmaceuticals, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
434 434
43% 43%
100%
- Direct Costs 94 94
63% 63%
22%
340 340
39% 39%
78%
- Selling and Administrative Expenses 126 126
80% 80%
29%
- Research and Development Expense 91 91
358% 358%
21%
123 123
21% 21%
28%
- Depreciation and Amortization 37 37
122% 122%
8%
EBIT (Operating Income) EBIT 86 86
38% 38%
20%
Net Profit 68 68
41% 41%
16%

In millions USD.

Don't miss a Thing! We will send you all news about Catalyst Pharmaceuticals, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Catalyst Pharmaceuticals, Inc. Stock News

Neutral
GlobeNewsWire
4 days ago
CORAL GABLES, Fla., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today announced that its sub-licensee in Japan, DyDo Pharma, Inc., ("DyDo") has reported that the Ministry of H...
Neutral
GlobeNewsWire
16 days ago
Ad hoc announcement pursuant to Art. 53 LR A conference call will be held on September 12, 2024, at 14:30 CEST / 13:30 BST / 08:30 EDT.
Neutral
GlobeNewsWire
about one month ago
CORAL GABLES, Fla., Aug. 20, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that Richard J. Daly, President and CEO of Catalyst, along with other mem...
More Catalyst Pharmaceuticals, Inc. News

Company Profile

Catalyst Pharmaceuticals is a biopharmaceutical company, which engages in the development and commercialization of therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases, including Lambert-Eaton myasthenic syndrome (LEMS), congenital myasthenic syndromes (CMS), MuSK antibody positive myasthenia gravis, spinal muscular atrophy (SMA) type 3, and infantile spasms. The company was founded by Huckel E. Hubert and Patrick J. McEnany in January 2002 and is headquartered in Coral Gables, FL.

Head office United States
CEO Richard Daly
Employees 167
Founded 2002
Website www.catalystpharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today